We are live on ! Find out more
RXST icon

RxSight
RXST

115 hedge funds and large institutions have $637M invested in RxSight in 2023 Q2 according to their latest regulatory filings, with 48 funds opening new positions, 45 increasing their positions, 13 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,345% more call options, than puts

Call options by funds: $1.42M | Put options by funds: $98K

586% more first-time investments, than exits

New positions opened: 48 | Existing positions closed: 7

246% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 13

141% more capital invested

Capital invested by funds: $264M → $637M (+$373M)

55% more funds holding

Funds holding: 74 → 115 (+41)

18.17% more ownership

Funds ownership: 46.92% → 65.09% (+18%)

Holders
115
Holders Change
+41
Holders Change %
+55.41%
% of All Funds
1.81%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.02%
New
48
Increased
45
Reduced
13
Closed
7
Calls
$1.42M
Puts
$98K
Net Calls
+$1.32M
Net Calls Change
+$283K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$32.3M
2
Lord, Abbett & Co
Lord, Abbett & Co
New Jersey
+$24.3M
3
Millennium Management
Millennium Management
New York
+$12.2M
4
ACM
Atika Capital Management
New York
+$11.4M
5
BlackRock
BlackRock
New York
+$8.5M

Top Sellers

Rank Fund Capital Flow
1
O
OrbiMed
New York
-$20.1M
2
Artisan Partners
Artisan Partners
Wisconsin
-$12.6M
3
BAM
Belpointe Asset Management
Nevada
-$1.76M
4
BM
Bridger Management
New York
-$1.65M
5
MF
Magnetar Financial
Illinois
-$1.47M
Name Holding Trade Value Shares
Change 		Change in
Stake
IA
101
IFP Advisors
Florida
$112K +$86.4K +3,882 New
AB
102
Amalgamated Bank
New York
$111K +$16.3K +734 +24%
CCMI
103
Creative Capital Management Investments
California
$92.7K – – –
Lazard Asset Management
104
Lazard Asset Management
New York
$70K +$54.4K +2,447 New
AIP
105
Ameritas Investment Partners
Nebraska
$64.5K +$7.36K +331 +17%
Royal Bank of Canada
106
Royal Bank of Canada
Ontario, Canada
$62K -$2.02K -91 -4%
NA
107
NewEdge Advisors
Louisiana
$57K -$3.11K -140 -7%
MLICM
108
Metropolitan Life Insurance Company (MetLife)
New York
$40.5K – – –
MA
109
MCF Advisors
Kentucky
$29.2K -$1.11K -50 -5%
Fidelity Investments
110
Fidelity Investments
Massachusetts
$22.3K +$1.04K +47 +6%
Osaic Holdings
111
Osaic Holdings
Arizona
$12.6K +$9.72K +437 New
TRCT
112
Tower Research Capital (TRC)
New York
$9.88K -$4.89K -220 -39%
FWM
113
Focused Wealth Management
New York
$1.73K – – –
CAL
114
Capital Advisors Ltd
Ohio
$1K – – –
Nisa Investment Advisors
115
Nisa Investment Advisors
Missouri
$202 – – –
O
116
OrbiMed
New York
– -$20.1M -1,202,833 Closed
BAM
117
Belpointe Asset Management
Nevada
– -$1.76M -105,250 Closed
BM
118
Bridger Management
New York
– -$1.65M -99,100 Closed
MF
119
Magnetar Financial
Illinois
– -$1.47M -88,236 Closed
SCM
120
Soleus Capital Management
Connecticut
– -$1.33M -80,000 Closed
XT
121
XTX Topco
Cayman Islands
– -$280K -16,763 Closed
BFM
122
Boothbay Fund Management
New York
– -$269K -16,108 Closed
1 2 3 4
5

RXST Hedge Fund Activity: Q2 2023 in Review

115 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in RxSight (RXST) for Q2 2023, worth a combined $637M — up 141% from $264M a quarter earlier.

Buyers outnumbered sellers: 48 funds opened new RXST positions and 7 closed out — a net gain of 41 holders — while 45 added to existing stakes and 13 trimmed.

The largest buyer was Morgan Stanley, adding an estimated $32.3M. The largest seller was OrbiMed, exiting entirely with an estimated $20.1M sold.

  • 115 institutional investors held RxSight (RXST) as of Q2 2023, up from 74 in Q1 2023.
  • Funds reported $637M of RxSight stock for Q2 2023, up 141% quarter-over-quarter.
  • 48 funds opened new RxSight positions in Q2 2023 and 7 closed out, a net change of +41 holders.
  • The largest RxSight buyer in Q2 2023 was Morgan Stanley, an estimated $32.3M added.
  • The largest RxSight seller in Q2 2023 was OrbiMed, an estimated $20.1M sold.

Based on aggregated 13F filings for Q2 2023.